Rogers D F, Laurent G J
National Heart and Lung Institute, Imperial College, London, UK.
Thorax. 1998 Mar;53(3):200-3. doi: 10.1136/thx.53.3.200.
There is a continuing need for development of new treatments for lung disease. Basic scientific investigations are identifying novel targets for the development of new approaches to therapy of a range of respiratory conditions. Coupled with the advances in technology being harnessed by the pharmaceutical and biotechnological industries, there is now an impressive range of potential treatments including gene therapy, not just for cystic fibrosis but also for a range of inflammatory lung conditions, anti-cytokine and anti-adhesion molecule approaches, and targeting of intracellular signal transduction pathways including cyclic AMP metabolism, tyrosine kinases and MAP kinases. "Old" molecules such as heparin and secretory leukoprotease inhibitor (SLPI) are demonstrating new beneficial activities. Simple molecules such as nitric oxide (NO) gas may be involved in the pathophysiology of different airway conditions. It is an exciting time for respiratory science and a time for optimism for those seeking new approaches to the treatment of lung diseases.
持续需要开发针对肺部疾病的新疗法。基础科学研究正在确定一系列呼吸疾病新治疗方法开发的新靶点。随着制药和生物技术行业利用技术的进步,现在有一系列令人瞩目的潜在治疗方法,包括基因疗法,不仅用于囊性纤维化,还用于一系列炎症性肺部疾病、抗细胞因子和抗粘附分子方法,以及针对细胞内信号转导途径,包括环磷酸腺苷代谢、酪氨酸激酶和丝裂原活化蛋白激酶。诸如肝素和分泌性白细胞蛋白酶抑制剂(SLPI)等“老”分子正在展现出新的有益活性。诸如一氧化氮(NO)气体等简单分子可能参与不同气道疾病的病理生理学。对于呼吸科学来说,这是一个激动人心的时代,对于那些寻求肺部疾病新治疗方法的人来说,也是一个充满乐观的时代。